Your browser doesn't support javascript.
loading
Research progress of anti-fibrotic drugs that inhibit epithelial-mesenchymal transition in pulmonary fibrosis / 中华劳动卫生职业病杂志
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-970716
Biblioteca responsável: WPRO
ABSTRACT
Pulmonary fibrosis is the end-stage pathological change of lung diseases, which seriously affects the respiratory function of human body. A large number of studies at home and abroad have confirmed that epithelial-mesenchymal transition (EMT) is an important intermediate stage in the development of pulmonary fibrosis. Inhibition of multiple pathways upstream and downstream of EMT, such as the classical Smads pathway and non-Smads pathway of TGF-1 can effectively inhibit the process of EMT and alleviate pulmonary fibrosis. This article will review the main conclusions of the mechanism of action of EMT as a target to improve the pathology of pulmonary fibrosis so far, and provide a theoretical basis and research direction for further research and development of anti-pulmonary fibrosis drugs.
Assuntos

Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Fibrose Pulmonar / Fibrose / Transdução de Sinais / Fator de Crescimento Transformador beta1 / Transição Epitelial-Mesenquimal / Antifibróticos Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Industrial Hygiene and Occupational Diseases Ano de publicação: 2023 Tipo de documento: Artigo
Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Fibrose Pulmonar / Fibrose / Transdução de Sinais / Fator de Crescimento Transformador beta1 / Transição Epitelial-Mesenquimal / Antifibróticos Limite: Humanos Idioma: Chinês Revista: Chinese Journal of Industrial Hygiene and Occupational Diseases Ano de publicação: 2023 Tipo de documento: Artigo
...